Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6065817 | Journal of Allergy and Clinical Immunology | 2014 | 8 Pages |
Abstract
This is the first report showing rapid improvement of the AD molecular signature with targeted anti-IL-4 receptor α therapy. These data suggest that IL-4 and IL-13 drive a complex, TH2-centered inflammatory axis in patients with AD.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jennifer D. PhD, Mayte PhD, Nikhil BS, Irma MSc, Xuan PhD, Ana PhD, Jeffrey E. MD, PhD, Allen R. MD, James G. MD, Neil MD, George D. MD, PhD, Gianluca MD, PhD, Emma MD, PhD,